Clinical Trial Update: Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating super selective intra-arterial cetuximab with reirradiation for relapsed or refractory glioblastoma, anaplastic astrocytoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligoastrocytoma
• Glioblastoma

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Northwell Health | Conditions: Glioblastoma, Anaplastic Astrocytoma | Phase 2 | Status: RECRUITING